Advertising Industry's Largest Competition
Recognizes Apyx Medical Device Campaign for Excellence in the Art
of Advertising
CLEARWATER, Fla., March 27,
2023 /PRNewswire/ -- Apyx Medical Corporation
(NASDAQ:APYX), the manufacturer of the proprietary helium
plasma and radiofrequency technology marketed and sold as
Renuvion®, today announced that it has won an award from
the American Advertising Federation for the Best Integrated
Advertising Campaign on its #ThisIsMe campaign. Developed in
partnership with luxury branding agency Lombardo, the campaign
represents the company's first ever direct-to-consumer brand
campaign.
The national campaign is completely revolutionary for this
industry, connecting with patients along their personal journey
with approachable stories in their own words—empowering audiences
to make the ultimate statement: #ThisIsMe.
"It is a pleasure to help make a positive impact for Renuvion
and consumers with the #ThisIsMe campaign," says
Rita Lombardo, Agency Partner
and Director of Strategy. "To win an ADDY Award in addition just
proves that the Renuvion vision and message deeply resonates with
people and shifts the category forward."
"For too long the category has focused on what a person needed
to fix, rather than letting people express themselves," says
Jeff Hoffman, Vice President
of Marketing. "By tying into the emotional benefit of Renuvion,
#ThisIsMe speaks to a new generation of potential patients
who are open about discussing cosmetic procedures."
The key personas targeted by the campaign represent strategic
audiences, and the messaging shares how Renuvion allows individuals
to define themselves, owning their look.
The visuals of the campaign are elevated to appeal to an
audience that aligns more closely with beauty and fashion than with
the type of imagery commonly associated with "medical advertising."
In doing so, #ThisIsMe shifts the narrative around cosmetic
procedures forward.
Renuvion reaches audiences throughout the U.S. with the
#ThisIsMe campaign via TV spots accompanied by digital,
social, and upcoming outdoor advertising as part of an aggressive
omnichannel strategy to boost awareness and drive patients to
physician providers. The brand and its devices are already a
favorite among the top plastic surgeons and cosmetic physicians in
the world.
About Apyx Medical Corporation:
Apyx Medical Corporation is an advanced energy technology
company with a passion for elevating people's lives through
innovative products, including its Helium Plasma Technology
products marketed and sold as Renuvion® in the cosmetic
surgery market and J-Plasma® in the hospital surgical
market. Renuvion® and J-Plasma® offer
surgeons a unique ability to provide controlled heat to tissue to
achieve their desired results. The Company also leverages its deep
expertise and decades of experience in unique waveforms through OEM
agreements with other medical device manufacturers. For further
information about the Company and its products, please refer to the
Apyx Medical Corporation website at www.ApyxMedical.com.
About Lombardo:
Lombardo is a creative agency based on the Palm Beach waterfront, with offices in
New York and Los Angeles. Since 2010, Lombardo gained a
reputation for exceptional creative and bespoke service. Their work
with both market leaders and challenger brands has changed the way
industries operate and generated significant value for clients and
communities alike. These attributes have seen them develop a client
list that includes Fendi, Watches of Switzerland, and Anheuser-Busch.
Cautionary Statement on Forward-Looking Statements
Certain matters discussed in this release and oral statements
made from time to time by representatives of the Company may
constitute forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995 and the Federal
securities laws. Although the Company believes that the
expectations reflected in such forward-looking statements are based
upon reasonable assumptions, it can give no assurance that its
expectations will be achieved.
All statements other than statements of historical fact are
statements that could be deemed forward-looking statements,
including but not limited to, any statements regarding the
potential impact of the COVID-19 pandemic and the actions by
governments, businesses and individuals in response to the
situation; projections of net revenue, margins, expenses, net
earnings, net earnings per share, or other financial items;
projections or assumptions concerning the possible receipt by the
Company of any regulatory approvals from any government agency or
instrumentality including but not limited to the U.S. Food and Drug
Administration, supply chain disruptions, component shortages,
manufacturing disruptions or logistics challenges; or macroeconomic
or geopolitical matters and the impact of those matters on the
Company's financial performance.
Forward-looking statements and information are subject to
certain risks, trends and uncertainties that could cause actual
results to differ materially from those projected. Many of these
factors are beyond the Company's ability to control or predict.
Important factors that may cause the Company's actual results to
differ materially and that could impact the Company and the
statements contained in this release include but are not limited to
risks, uncertainties and assumptions relating to the regulatory
environment in which the Company is subject to, including the
Company's ability to gain requisite approvals for its products from
the U.S. Food and Drug Administration and other governmental and
regulatory bodies, both domestically and internationally; the
impact of the recent FDA Safety Communication on our business and
operations; factors relating to the effects of the COVID-19
pandemic; sudden or extreme volatility in commodity prices and
availability, including supply chain disruptions; changes in
general economic, business or demographic conditions or trends;
changes in and effects of the geopolitical environment; liabilities
and costs which the Company may incur from pending or threatened
litigations, claims, disputes or investigations; and other risks
that are described in the Company's Annual Report on Form 10-K for
the fiscal year ended December 31,
2022 and the Company's other filings with the Securities and
Exchange Commission. For forward-looking statements in this
release, the Company claims the protection of the safe harbor for
forward-looking statements contained in the Private Securities
Litigation Reform Act of 1995. The Company assumes no obligation to
update or supplement any forward-looking statements whether as a
result of new information, future events or otherwise.
Media Contact:
Jane Sparango
Coterie Media (for Renuvion)
jane@coteriemedia.com
310-339-1214
Investor Relations Contact:
ICR Westwicke on behalf of Apyx Medical Corporation
Mike Piccinino, CFA
investor.relations@apyxmedical.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/renuvion-wins-addy-award-for-thisisme-campaign-301781728.html
SOURCE Renuvion